Last reviewed · How we verify
CD19/79b Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi-specific CAR-T cells and their persistency in patients.
Details
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | Thu Jun 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- B Cell Malignancies
Interventions
- bi-4SCAR CD19/79b T cells
Countries
China